Enlivex Therapeutics Statistics Share Statistics Enlivex Therapeutics has 23.85M
shares outstanding. The number of shares has increased by 11.42%
in one year.
Shares Outstanding 23.85M Shares Change (YoY) 11.42% Shares Change (QoQ) 8.46% Owned by Institutions (%) 14.49% Shares Floating 21.35M Failed to Deliver (FTD) Shares 2,879 FTD / Avg. Volume 0.53%
Short Selling Information The latest short interest is 310.42K, so 1.45% of the outstanding
shares have been sold short.
Short Interest 310.42K Short % of Shares Out 1.45% Short % of Float 1.54% Short Ratio (days to cover) 1.41
Valuation Ratios The PE ratio is -1.6 and the forward
PE ratio is -1.78.
Enlivex Therapeutics's PEG ratio is
0.03.
PE Ratio -1.6 Forward PE -1.78 PS Ratio 0 Forward PS n/a PB Ratio 1.02 P/FCF Ratio -1.83 PEG Ratio 0.03
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Enlivex Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 6.84,
with a Debt / Equity ratio of 0.02.
Current Ratio 6.84 Quick Ratio 6.84 Debt / Equity 0.02 Debt / EBITDA -0.04 Debt / FCF -0.04 Interest Coverage -1195.08
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-211.46K Employee Count 71 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -37.2% in the
last 52 weeks. The beta is 0.83, so Enlivex Therapeutics's
price volatility has been higher than the market average.
Beta 0.83 52-Week Price Change -37.2% 50-Day Moving Average 1.2 200-Day Moving Average 1.11 Relative Strength Index (RSI) 40.06 Average Volume (20 Days) 543,819
Income Statement
Revenue n/a Gross Profit -545K Operating Income -15.54M Net Income -15.01M EBITDA -14.47M EBIT -15.01M Earnings Per Share (EPS) -0.73
Full Income Statement Balance Sheet The company has 3.3M in cash and 534K in
debt, giving a net cash position of 2.77M.
Cash & Cash Equivalents 3.3M Total Debt 534K Net Cash 2.77M Retained Earnings -127.11M Total Assets 22.6M Working Capital 18M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -13.01M
and capital expenditures -103K, giving a free cash flow of -13.11M.
Operating Cash Flow -13.01M Capital Expenditures -103K Free Cash Flow -13.11M FCF Per Share -0.64
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields ENLV does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for ENLV is $10,
which is 870.9% higher than the current price. The consensus rating is "Buy".
Price Target $10 Price Target Difference 870.9% Analyst Consensus Buy Analyst Count 2
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Mar 6, 2019. It was a
backward
split with a ratio of 1:8.
Last Split Date Mar 6, 2019 Split Type backward Split Ratio 1:8
Scores Altman Z-Score -5.26 Piotroski F-Score 1
